Activity

The US FDA, Pending The Clinical Benefit Study, Has Conditionally Approved The First New Alzheimer’s Disease Drug, Since A Drug Was Last Approved In Almost 20 Years, In 2003. The Novel Experimental Drug, Known As Aducanumab Or Aduhelm, Is Intended For Patients With Earliest Stage Of Dementia, And To Slow Alzheimer’s Disease Progression.

https://www.cnn.com/2021/06/07/health/alzheimers-drug-aducanumab-fda-approved-wellness/index.html

The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer’s disease — despite an FDA advisory committee concluding last year that there is not enough evidence to support the effectiveness of the treatment.